It depends on the circumstances of the patient, but there are three emerging indications for RT in the setting of CAR T-cell therapy: Tumor debulking prior to CAR T-cell infusion Bridging therapy between apheresis and CAR T-cell infusion Salvage of refractory, progressive or relapsed disease fo...

Radiation can be incorporated with CAR-T in the bridging, consolidative and/or salvage setting.Bridging radiotherapy benefits patients who present with: Rapidly progressive disease that needs to be controlled during the CAR-T manufacturing period (3-6 weeks). Lymphoma at this stage is chemoresistan...

Chimeric antigen receptor (CAR) T-cell therapy has been approved by the US Food and Drug Administration and other regulatory agencies for patients with R/R DLBCL (including high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma) after 1-2 prior lines of ...